---
title: Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
nct_id: NCT00352898
overall_status: COMPLETED
phase: PHASE2
sponsor: GlaxoSmithKline
study_type: INTERVENTIONAL
primary_condition: Mumps
countries: Canada, Italy
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00352898.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00352898"
ct_last_update_post_date: 2016-10-07
last_seen_at: "2026-05-12T06:37:32.313Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

**Official Title:** Comparative Study Evaluating the Immunogenicity & Safety of MeMuRu-OKA Vaccine & Measles-mumps-rubella Vaccine (Priorix™) Co-administered With Varicella Vaccine (Varilrix™) in Children Primed With Both Measles-mumps-rubella & Varicella Vaccines

**NCT ID:** [NCT00352898](https://clinicaltrials.gov/study/NCT00352898)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 400
- **Lead Sponsor:** GlaxoSmithKline
- **Conditions:** Mumps, Rubella, Measles, Varicella
- **Start Date:** 2006-04
- **Completion Date:** 2006-11
- **CT.gov Last Update:** 2016-10-07

## Brief Summary

Since measles-mumps-rubella (MMR) and varicella vaccinations are established as routine childhood practice and often co-administered during the second year of life, a combined measles-mumps-rubella-varicella (MeMuRu-OKA) vaccine is fully justified. Such a combined vaccine was developed and extensively studied in susceptible children. In countries where varicella mass-vaccination is already implemented, a transition period is necessary as children who started with separate first-dose vaccinations of MMR and varicella will receive a single shot of the combined vaccine as the second dose. To account for those situations, this study will evaluate the effect of the combined measles-mumps-rubella-varicella vaccine given in place of separate MMR and varicella vaccines as a second dose.

## Eligibility

- **Minimum age:** 15 Months
- **Maximum age:** 6 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Children must be healthy to participate

Exclusion Criteria:

* immunosuppressive (including HIV) conditions, allergic diseases, neurological disorders, known anaphylactic reaction to MMR vaccine, and fever (axillary temperature ³ 37.5°C at the time of vaccination) are excluding factors. Children must have received one dose (but not more) of MMR and of varicella vaccine at least 6 weeks before entering the study. They must not receive or have received other non-registered drug or vaccine within 30 days prior to study start, or immunosuppressants for more than 14 days. Immunoglobulins or any blood products are prohibited during the 6 months before and during the study, as well as vaccine other than that foreseen by the protocol, 30 days before until 56 days after vaccination. They must not have had measles, mumps, rubella or varicella, or have been exposed to those diseases within 30 days prior to study start. New-born infants (\< 5 weeks of age), pregnant women without previous exposure to chickenpox, and immunodeficient persons cannot live in the same household as the vaccinated child.
```

## Interventions

- **MeMuRu-OKA (study vac)** (BIOLOGICAL)
- **MMR, Varicella vacc (control)** (BIOLOGICAL)

## Primary Outcomes

- **Varicella, MMR titres at 42-56 days after first vaccination**

## Secondary Outcomes

- **Seropositivity rates. Safety: solicited local/general, unsolicited AEs (42 days), SAEs (whole study)**

## Locations (6)

- GSK Investigational Site, Edmonton, Alberta, Canada
- GSK Investigational Site, Vancouver, British Columbia, Canada
- GSK Investigational Site, Halifax, Nova Scotia, Canada
- GSK Investigational Site, Enna, Sicily, Italy
- GSK Investigational Site, Ragusa, Sicily, Italy
- GSK Investigational Site, San Gregorio Di Catania (CT), Sicily, Italy

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.gsk investigational site|edmonton|alberta|canada` — added _(2026-05-12)_
- `locations.gsk investigational site|vancouver|british columbia|canada` — added _(2026-05-12)_
- `locations.gsk investigational site|halifax|nova scotia|canada` — added _(2026-05-12)_
- `locations.gsk investigational site|enna|sicily|italy` — added _(2026-05-12)_
- `locations.gsk investigational site|ragusa|sicily|italy` — added _(2026-05-12)_
- `locations.gsk investigational site|san gregorio di catania (ct)|sicily|italy` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00352898.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00352898*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*